Veterinary Medicines

Nobivac DHP live vet. Frystorkat pulver och vätska till injektionsvätska, suspension

Authorised
  • Water
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine distemper virus, strain Onderstepoort, Live
Download as PDF

Product identification

Medicine name:
Nobivac DHP live vet. Frystorkat pulver och vätska till injektionsvätska, suspension
Active substance:
  • Water
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine distemper virus, strain Onderstepoort, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Water
    1.00
    millilitre(s)
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan LPV3, Live
    4.00
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Canine distemper virus, strain Onderstepoort, Live
    4.00
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Oriola Sweden AB
  • Intervet International B.V.
Responsible authority:
  • Medical Products Agency
Authorisation number:
  • 11373
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."